Therefore, inhibition of LDHA activity by exploring DIO3OS knockdown approaches could re-sensitize breast tumor cells to anti-HER2 therapies (trastuzumab) or chemotherapies (paclitaxel) as a breast cancer treatment target (33). Here, ERBB2 is linked to breast cancer.